Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: NMSS analysis from the BIPARK-I double-blind experience
Objective: To evaluate the impact on non-motor symptoms in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: Opicapone (OPC), a new once-daily COMT…Switching from double-blind entacapone or placebo to open-label opicapone: NMSS results of the 1-year extension BIPARK-I study
Objective: To evaluate the impact on non-motor symptoms in levodopa-treated Parkinson’s disease (PD) patients who switched from placebo (PLC) or entacapone (ENT) to opicapone (OPC)…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: UPDRS-II and III analysis from the BIPARK-I double-blind experience
Objective: To evaluate the impact on UPDRS-II and III in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: Opicapone (OPC), a novel once-daily…ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subjects
Objective: To study the dose effects of a novel catechol-O-methyl transferase (COMT) inhibitor ODM-104 and the aromatic L-amino acid decarboxylase (AADC) inhibitor carbidopa on levodopa…Acute efficacy and tolerability of the COMT inhibitor opicapone
Objective: Evaluation of the acute efficacy and tolerability of Opicapone. Background: Opicapone is a Catechol-O-Methyltransferase (COMT) inhibitor for the treatment of patients with idiopathic Parkinson’s…Influence of baseline OFF-time in the efficacy response of opicapone in Parkinson’s disease patients with motor fluctuations: The BIPARK-I double-blind experience
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and subdivided by their baseline OFF-time. Background: OPC,…A novel non-nitrocatechol COMT inhibitor ODM-104 shows superior pharmacodynamic effects to entacapone
Objective: ODM-104 is a novel non-nitrocatechol catechol-O-methyltransferase (COMT) inhibitor that is undergoing clinical evaluation for Parkinson’s disease (PD). This study investigated the pharmacodynamic effects of…Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results of the 1-year extension BIPARK-I study
Objective: To evaluate the impact on UPDRS-II and III in levodopa-treated Parkinson’s Disease (PD) patients who switched from placebo (PLC) or entacapone (ENT) to opicapone…ON-time evolution following one-year open-label opicapone: BIPARK-I study
Objective: ON-time evolution following 1-year, open-label (OL), once-daily (QD) opicapone (OPC) treatment in patients with Parkinson’s disease (PD) on levodopa-therapy and with motor fluctuations. Background:…How to switch from Entacapone to Opicapone based on BIPARK-I study experience
Objective: To clarify how easily can entacapone (ENT) be switched to opicapone (OPC), in levodopa-treated patients with Parkinson’s disease (PD) and motor-fluctuations. Background: OPC, a…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.